CD274 and head and neck squamous cell carcinoma: For example, the multinational, Phase III, double-blind, placebo-controlled JAVELIN Head and Neck 100 trial (NCT02952586) is assessing whether adding the PD-L1 inhibitor avelumab to standard cisplatin-based chemoradiotherapy improves progression-free and overall survival compared with chemoradiotherapy plus placebo in patients with high-risk, nonmetastatic, locoregionally advanced HNSCC [245].